How much funding has Firefly Biologics raised?

Firefly Biologics has raised $94.0M in total funding, most recently a Series A round.

Who are Firefly Biologics's investors?

Firefly Biologics's investors include Jerel Davis, MPM Capital, Decheng Capital, Eli Lilly, Samsara BioCapital, Amplitude Ventures.

Where is Firefly Biologics headquartered?

Firefly Biologics is headquartered in South San Francisco.

What industry is Firefly Biologics in?

Firefly Biologics operates in Biotech.

How many employees does Firefly Biologics have?

Firefly Biologics has 11-50 employees.

Firefly Biologics

Closed

South San Francisco · $94.0M raised

Biotech

Headquarters: South San Francisco
Employees: 11–50
Business Model: B2B
Website: fireflybiologics.com

Total Funding: $94.0M
Last Round: $94.0M Series AMar 2024
Rounds: 1

About

Firefly Bio (dba Firefly Biologics) is a South San Francisco-based biotech developing Degrader Antibody Conjugates (DACs), a new therapeutic class combining the tumor-targeting precision of antibody-drug conjugates with selective protein degrader payloads. The company assembled a leadership team of veteran ADC researchers and is backed by Decheng Capital, MPM BioImpact, and Versant Ventures, having raised a $94 million Series A financing round to advance its pipeline.

Summary

Firefly Biologics is a Biotech company based in South San Francisco. It has raised $94.0M in total across 1 round, most recently a $94.0M Series A round in Mar 2024. Investors include Jerel Davis, MPM Capital and Decheng Capital.